TULIP Extension trial shows #SLE Rx w/ anifrolumab + SOC had less organ damage after 208wks. 354 on ANIF (+SOC) vs 561 on SOC alone = ANIF was 59.9% lower SDI (SLE damage index) (HR 0.40) vs those on SOC alone at wk 208. https://t.co/Ox7efMsAW2 https://t.co/55jZBE2aTW